Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Vanda Pharma: Trading Below Cash With Upcoming Catalysts Expected 2H12Mike Havrilla • Wed, Jun 13, 2012
-
SAC Capital Discloses Vanda Pharmaceuticals StakeMarket Folly • Thu, Jun 11, 2009
To learn more about Seeking Alpha Pro, click here.
-
Put Options Active On AmerisourceBergenInteractive Brokers • Tue, Jun 11
-
5 Biotech Winners From Last Week With High Short RatiosHeisenberg Principle • Mon, Dec 24, 2012
-
10 High-Growth Stocks Under $5 Undervalued By Levered Free Cash FlowsKapitall • Thu, Jul 26, 2012
-
6 Highly Liquid Biotech Stocks With Positive Correlation To VolatilityKapitall • Tue, Jan 31, 2012
-
Vanda Pharmaceuticals, Inc. Q4 2009 Earnings Call TranscriptTue, Feb 16, 2010
-
Vanda Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Vanda Pharmaceuticals Inc. Q1 2008 Earnings Call TranscriptThu, May 22, 2008
-
Vanda Pharmaceuticals Q4 2007 Earnings Call TranscriptMon, Apr 7, 2008
-
PR Newswire (Jun 5, 2013)
-
PR Newswire (May 31, 2013)
-
PR Newswire (May 30, 2013)
-
PR Newswire (May 23, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (Apr 18, 2013)
-
PR Newswire (Apr 17, 2013)
-
Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry ConferencePR Newswire (Apr 4, 2013)
-
PR Newswire (Mar 14, 2013)
-
at CNBC.com (Mar 5, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 22, 2013)
-
PR Newswire (Dec 18, 2012)
-
PR Newswire (Dec 13, 2012)
-
PR Newswire (Nov 7, 2012)
VNDA vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with exclusive worldwide commercial rights to two product candidates in clinical development. We believe that each of our product... More








